Type 2 Diabetes - Pipeline Review, H2 2020

November 2020 | 1251 pages | ID: TBD9F1A0B80EN
Global Markets Direct

Abstracts

Type 2 Diabetes - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Pipeline Review, H2 2020, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.

Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 15, 1, 40, 64, 75, 3, 7, 232, 43 and 11 respectively. Similarly, the Universities portfolio in Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 2, 61 and 18 molecules, respectively.

Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Type 2 Diabetes- Overview
Type 2 Diabetes- Therapeutics Development
Type 2 Diabetes- Therapeutics Assessment
Type 2 Diabetes- Companies Involved in Therapeutics Development
Type 2 Diabetes- Drug Profiles
Type 2 Diabetes- Dormant Projects
Type 2 Diabetes- Discontinued Products
Type 2 Diabetes- Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Type 2 Diabetes, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Type 2 Diabetes - Pipeline by 3SBio Inc, H2 2020
Type 2 Diabetes - Pipeline by Adare Pharma Solutions, H2 2020
Type 2 Diabetes - Pipeline by ADM Therapeutics, H2 2020
Type 2 Diabetes - Pipeline by Adocia SAS, H2 2020
Type 2 Diabetes - Pipeline by Aerami Therapeutics, H2 2020
Type 2 Diabetes - Pipeline by Afimmune Biopharma Ltd, H2 2020
Type 2 Diabetes - Pipeline by AgeX Therapeutics Inc, H2 2020
Type 2 Diabetes - Pipeline by Akero Therapeutics Inc, H2 2020
Type 2 Diabetes - Pipeline by Akston Biosciences Corp, H2 2020
Type 2 Diabetes - Pipeline by Algiax Pharmaceuticals GmbH, H2 2020
Type 2 Diabetes - Pipeline by Alms Therapeutics, H2 2020
Type 2 Diabetes - Pipeline by AlphaMab Co Ltd, H2 2020
Type 2 Diabetes - Pipeline by Amgen Inc, H2 2020
Type 2 Diabetes - Pipeline by AmideBio LLC, H2 2020
Type 2 Diabetes - Pipeline by Anagenesis Biotechnologies SAS, H2 2020
Type 2 Diabetes - Pipeline by Anji Pharmaceuticals Inc, H2 2020
Type 2 Diabetes - Pipeline by AnyGen Co Ltd, H2 2020
Type 2 Diabetes - Pipeline by Apcegen Technologies Pvt Ltd, H2 2020
Type 2 Diabetes - Pipeline by Aphios Corp, H2 2020
Type 2 Diabetes - Pipeline by Apoglyx AB, H2 2020
Type 2 Diabetes - Pipeline by APT Therapeutics Inc, H2 2020
Type 2 Diabetes - Pipeline by Aptamer Sciences Inc, H2 2020
Type 2 Diabetes - Pipeline by AptamiR Therapeutics Inc, H2 2020
Type 2 Diabetes - Pipeline by Ariddad Therapeutics SL, H2 2020
Type 2 Diabetes - Pipeline by Arkay Therapeutics LLC, H2 2020
Type 2 Diabetes - Pipeline by Artery Therapeutics Inc, H2 2020
Type 2 Diabetes - Pipeline by AsiaBiome, H2 2020
Type 2 Diabetes - Pipeline by Astellas Pharma Inc, H2 2020
Type 2 Diabetes - Pipeline by AstraZeneca Plc, H2 2020
Type 2 Diabetes - Pipeline by Atrogi AB, H2 2020
Type 2 Diabetes - Pipeline by Auritec Pharmaceuticals Inc, H2 2020
Type 2 Diabetes - Pipeline by Avolynt Inc, H2 2020
Type 2 Diabetes - Pipeline by Beijing Eastern Biotech Co Ltd, H2 2020
Type 2 Diabetes - Pipeline by Beijing SL Pharmaceutical Co Ltd, H2 2020
Type 2 Diabetes - Pipeline by Betagenon AB, H2 2020
Type 2 Diabetes - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2020
Type 2 Diabetes - Pipeline by Biocon Ltd, H2 2020
Type 2 Diabetes - Pipeline by BioEos Ltd, H2 2020
Type 2 Diabetes - Pipeline by Biogenomics Ltd, H2 2020
Type 2 Diabetes - Pipeline by BioKier Inc, H2 2020
Type 2 Diabetes - Pipeline by BioLingus AG, H2 2020
Type 2 Diabetes - Pipeline by BioRestorative Therapies Inc, H2 2020
Type 2 Diabetes - Pipeline by Biozeus Pharmaceutical SA, H2 2020
Type 2 Diabetes - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Type 2 Diabetes - Pipeline by Bopin (Shanghai) Biomedical Technology Co Ltd, H2 2020
Type 2 Diabetes - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2020
Type 2 Diabetes - Pipeline by Boston Therapeutics Inc, H2 2020
Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H2 2020
Type 2 Diabetes - Pipeline by BrightGene Bio-Medical Technology Co Ltd, H2 2020
Type 2 Diabetes - Pipeline by Buto Biopharma Inc, H2 2020
Type 2 Diabetes - Pipeline by C4X Discovery Holdings Plc, H2 2020
Type 2 Diabetes - Pipeline by Cadila Healthcare Ltd, H2 2020
Type 2 Diabetes - Pipeline by Cadila Pharmaceuticals Ltd, H2 2020
Type 2 Diabetes - Pipeline by Caelus Health, H2 2020
Type 2 Diabetes - Pipeline by Caldan Therapeutics Ltd, H2 2020
Type 2 Diabetes - Pipeline by CAR-T (Shanghai) Biotechnology Co Ltd, H2 2020
Type 2 Diabetes - Pipeline by Carlina Technologies SAS, H2 2020
Type 2 Diabetes - Pipeline by Carmot Therapeutics Inc, H2 2020
Type 2 Diabetes - Pipeline by Cellix Bio Pvt Ltd, H2 2020
Type 2 Diabetes - Pipeline by Celon Pharma SA, H2 2020
Type 2 Diabetes - Pipeline by Centaurus Therapeutics Inc, H2 2020
Type 2 Diabetes - Pipeline by Vivus Inc, H2 2020
Type 2 Diabetes - Pipeline by vTv Therapeutics Inc, H2 2020
Type 2 Diabetes - Pipeline by Vybion Inc, H2 2020
Type 2 Diabetes - Pipeline by Wuxi Hebang Biotechnology Co Ltd, H2 2020
Type 2 Diabetes - Pipeline by XERIS Pharmaceuticals Inc, H2 2020
Type 2 Diabetes - Pipeline by XL-protein GmbH, H2 2020
Type 2 Diabetes - Pipeline by XOMA Corp, H2 2020
Type 2 Diabetes - Pipeline by XuanZhu Pharma Co Ltd, H2 2020
Type 2 Diabetes - Pipeline by Yichang Hec Changjiang Pharmaceutical Co Ltd, H2 2020
Type 2 Diabetes - Pipeline by Youngene Therapeutics Co Ltd, H2 2020
Type 2 Diabetes - Pipeline by Zealand Pharma AS, H2 2020
Type 2 Diabetes - Pipeline by Zhejiang Doer Biologics Corp, H2 2020
Type 2 Diabetes - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2020
Type 2 Diabetes - Pipeline by Zhejiang Huayang Pharmaceutical Co Ltd, H2 2020
Type 2 Diabetes - Pipeline by Zih Yuan Tang Biotechnology Co Ltd, H2 2020
Type 2 Diabetes - Pipeline by Zucara Therapeutics Inc, H2 2020
Type 2 Diabetes - Dormant Projects, H2 2020
Type 2 Diabetes - Discontinued Products, H2 2020

About

Type 2 Diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.

Global Markets Direct's latest report, 'Type 2 Diabetes - Pipeline Review, H2 2019', provides comprehensive information on the therapeutics under development for Type 2 Diabetes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Why should you buy this report?

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players and create effective counter-strategies to gain competitive advantage
• Identify important and diverse types of therapeutics under development for Type 2 Diabetes
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics